446 related articles for article (PubMed ID: 17196290)
1. Delivery of photosensitisers and light through mucus: investigations into the potential use of photodynamic therapy for treatment of Pseudomonas aeruginosa cystic fibrosis pulmonary infection.
Donnelly RF; McCarron PA; Cassidy CM; Elborn JS; Tunney MM
J Control Release; 2007 Feb; 117(2):217-26. PubMed ID: 17196290
[TBL] [Abstract][Full Text] [Related]
2. Delivery of Methylene Blue and meso-tetra (N-methyl-4-pyridyl) porphine tetra tosylate from cross-linked poly(vinyl alcohol) hydrogels: a potential means of photodynamic therapy of infected wounds.
Donnelly RF; Cassidy CM; Loughlin RG; Brown A; Tunney MM; Jenkins MG; McCarron PA
J Photochem Photobiol B; 2009 Sep; 96(3):223-31. PubMed ID: 19651522
[TBL] [Abstract][Full Text] [Related]
3. Potential of photodynamic therapy in treatment of fungal infections of the mouth. Design and characterisation of a mucoadhesive patch containing toluidine blue O.
Donnelly RF; McCarron PA; Tunney MM; David Woolfson A
J Photochem Photobiol B; 2007 Jan; 86(1):59-69. PubMed ID: 16963273
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic Antimicrobial Chemotherapy (PACT) in combination with antibiotics for treatment of Burkholderia cepacia complex infection.
Cassidy CM; Donnelly RF; Elborn JS; Magee ND; Tunney MM
J Photochem Photobiol B; 2012 Jan; 106():95-100. PubMed ID: 22079165
[TBL] [Abstract][Full Text] [Related]
5. Effect of sub-lethal challenge with Photodynamic Antimicrobial Chemotherapy (PACT) on the antibiotic susceptibility of clinical bacterial isolates.
Cassidy CM; Donnelly RF; Tunney MM
J Photochem Photobiol B; 2010 Apr; 99(1):62-6. PubMed ID: 20207552
[TBL] [Abstract][Full Text] [Related]
6. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
7. Drug and light delivery strategies for photodynamic antimicrobial chemotherapy (PACT) of pulmonary pathogens: a pilot study.
Cassidy CM; Tunney MM; Magee ND; Elborn JS; Bell S; Singh TR; Donnelly RF
Photodiagnosis Photodyn Ther; 2011 Mar; 8(1):1-6. PubMed ID: 21333929
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
[TBL] [Abstract][Full Text] [Related]
9. Toluidine blue O photodynamic inactivation on multidrug-resistant Pseudomonas aeruginosa.
Tseng SP; Teng LJ; Chen CT; Lo TH; Hung WC; Chen HJ; Hsueh PR; Tsai JC
Lasers Surg Med; 2009 Jul; 41(5):391-7. PubMed ID: 19533759
[TBL] [Abstract][Full Text] [Related]
10. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.
Bjarnsholt T; Jensen PØ; Fiandaca MJ; Pedersen J; Hansen CR; Andersen CB; Pressler T; Givskov M; Høiby N
Pediatr Pulmonol; 2009 Jun; 44(6):547-58. PubMed ID: 19418571
[TBL] [Abstract][Full Text] [Related]
11. Chelated iron sources are inhibitors of Pseudomonas aeruginosa biofilms and distribute efficiently in an in vitro model of drug delivery to the human lung.
Musk DJ; Hergenrother PJ
J Appl Microbiol; 2008 Aug; 105(2):380-8. PubMed ID: 18284482
[TBL] [Abstract][Full Text] [Related]
12. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways.
Hassett DJ; Sutton MD; Schurr MJ; Herr AB; Caldwell CC; Matu JO
Trends Microbiol; 2009 Mar; 17(3):130-8. PubMed ID: 19231190
[TBL] [Abstract][Full Text] [Related]
13. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
Murray TS; Egan M; Kazmierczak BI
Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667
[TBL] [Abstract][Full Text] [Related]
14. The approach to Pseudomonas aeruginosa in cystic fibrosis.
Bendiak GN; Ratjen F
Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
[TBL] [Abstract][Full Text] [Related]
15. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
[TBL] [Abstract][Full Text] [Related]
16. Effects of ginseng on Pseudomonas aeruginosa motility and biofilm formation.
Wu H; Lee B; Yang L; Wang H; Givskov M; Molin S; Høiby N; Song Z
FEMS Immunol Med Microbiol; 2011 Jun; 62(1):49-56. PubMed ID: 21303421
[TBL] [Abstract][Full Text] [Related]
17. How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?
VanDevanter DR; Van Dalfsen JM
Pediatr Pulmonol; 2005 Jun; 39(6):504-6. PubMed ID: 15830388
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis.
Burns JL; Gibson RL; McNamara S; Yim D; Emerson J; Rosenfeld M; Hiatt P; McCoy K; Castile R; Smith AL; Ramsey BW
J Infect Dis; 2001 Feb; 183(3):444-52. PubMed ID: 11133376
[TBL] [Abstract][Full Text] [Related]
19. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
Bahamondez-Canas TF; Zhang H; Tewes F; Leal J; Smyth HDC
Mol Pharm; 2018 Apr; 15(4):1643-1652. PubMed ID: 29514003
[TBL] [Abstract][Full Text] [Related]
20. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR; Pressler T; Høiby N
J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
